Amryt Pharma Past Earnings Performance
Past criteria checks 0/6
Amryt Pharma has been growing earnings at an average annual rate of 34.4%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 32.7% per year.
Key information
34.4%
Earnings growth rate
59.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 32.7% |
| Return on equity | -0.2% |
| Net Margin | -0.3% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions
Dec 09Chiasma surges on merger agreement with Amryt
May 05Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept
Feb 04Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder
Dec 23Amryt Group's Lojuxta receives marketing approval in Brazil
Dec 09Revenue & Expenses BreakdownBeta
How Amryt Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 244 | -1 | 124 | 38 |
| 30 Jun 22 | 239 | 3 | 119 | 41 |
| 31 Mar 22 | 233 | 3 | 112 | 39 |
| 31 Dec 21 | 223 | 1 | 100 | 38 |
| 30 Sep 21 | 210 | -88 | 90 | 34 |
| 30 Jun 21 | 203 | -81 | 83 | 30 |
| 31 Mar 21 | 186 | -92 | 82 | 28 |
| 31 Dec 20 | 183 | -105 | 81 | 28 |
| 30 Sep 20 | 180 | -87 | 80 | 31 |
| 30 Jun 20 | 140 | -92 | 68 | 26 |
| 31 Mar 20 | 98 | -87 | 52 | 23 |
| 31 Dec 19 | 58 | -63 | 36 | 16 |
| 31 Dec 18 | 17 | -30 | 18 | 11 |
Quality Earnings: AMYT is currently unprofitable.
Growing Profit Margin: AMYT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMYT is unprofitable, but has reduced losses over the past 5 years at a rate of 34.4% per year.
Accelerating Growth: Unable to compare AMYT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMYT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: AMYT has a negative Return on Equity (-0.24%), as it is currently unprofitable.